Biological Adaptations of Strength Training to Obese and Normal Weight Middle-aged Men
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Changes in HDL concentration
研究概览
简要总结
A two-trial repeated measures design will be employed in this investigation. Both the control trial and the exercise trial will last for 3 months. During a week before the start of the study, participants will complete dietary recalls and record their habitual physical activity using accelerometers. Thereafter, body composition, ultrasound imaging of the muscle and liver, biochemical and hematological markers were measured. This range of measurements will be repeated the ended each month for both trials. Control trial succeeds exercise trial. An exercise intervention program will take place in the second trial, three times a week.
详细描述
A sample size of 30 volunteers, aged 35-45 years, will participate in the present study. Of them, 15 will be normal weight and 15 will suffer from fatty liver disease (BMI 29-35 kg/m2, waist size >102 cm). The exclusion criteria will be a) medication, b) musculoskeletal problems that will prevent participation in the training program, c) known condition or medical condition preventing participation in the program e.g. hypertension, d) BMI> 35kg / m2, (e) a severe family medical history up to first degree relatives with cardiovascular disease and / or diabetes at the age of less than 65 for women and less than 55 years for men and (f) smoking. After informing and receiving a questionnaire and medical history, volunteers will sign for their participation in the survey.
A two-trial repeated measures design will be applied in this investigation. Both control and exercise trials will last for 3 months. During the week preceding the commencement of the study, participants will complete dietary recalls and will have their habitual physical activity monitored, by utilizing accelerometers. Thereafter, body composition, ultrasound imaging of muscle and liver, biochemical and hematological markers will be measured. The same measurements will be repeated at the end of each month, in both trials. Control trial will be executed prior to exercise trial. An exercise intervention program, combining strength and cardiovascular exercises performed three times a week, will take place in the exercise trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 50 Years(Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •no use of medication
- •free of musculoskeletal limitations
- •absence of a known condition or medical condition preventing participation in the program (e.g. hypertension)
- •absence of a severe family medical history up to first degree relatives with cardiovascular disease and /or diabetes at the age of less than 65 for women and less than 55 years for men
- •non-smokers
排除标准
- •use of medication
- •musculoskeletal limitations that will prevent participation in the training program
- •known condition or medical condition preventing participation in the program (e.g. hypertension)
- •a severe family medical history up to first degree relatives with cardiovascular disease and /or diabetes at the age of less than 65 for women and less than 55 years for men
结局指标
主要结局
Changes in HDL concentration
时间窗: At baseline as well as at 1,5 and 3 months in both trials
HDL concentration will be measured in blood
Changes in total cholesterol
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Total cholesterol levels will measured in blood
Changes in glycosylated hemoglobin
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Glycosylated hemoglobin levels will be measured in blood
Changes in total antioxidant capacity
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Total antioxidant capacity will be assessed in plasma
Changes in Red Blood Cells
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Red blood cells will be measured in bood samples
Changes in body composition
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Body composition will be assessed using Dual-energy-X-ray Absorptiometry (DXA) instrumentation
Changes in glucose
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Glucose concentration will be measured in blood
Changes in insulin
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Insulin concentration will be measured in blood
Changes in insulin resistance index
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Insulin resistance index will be calculated through glucose and insulin values
Changes in transaminases
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Transaminase levels will be measured in blood samples
Changes in C-reactive protein
时间窗: At baseline as well as at 1,5 and 3 months in both trials
C-reactive protein levels will be measured in blood samples
Changes in White Blood Cells
时间窗: At baseline as well as at 1,5 and 3 months in both trials
White blood cells will be measured in bood samples
Changes in Hemoglobin
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Hemoglobin will be measured in blood samples
Changes in Hematocrit
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Hematocrit levels will be measured in blood samples
Changes in protein carbonyls
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Protein carbonyl formation will be measured in serum
Changes in thiobarbituric acid reactive substances (TBARS)
时间窗: At baseline as well as at 1,5 and 3 months in both trials
TBARS will be measured in serum
Changes in catalase
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Catalase activity will be measured in serum
Changes in fatty infiltration of the liver
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Fatty infiltration of the liver will be assessed by ultrasound imaging of liver
Changes in LDL concentration
时间窗: At baseline as well as at 1,5 and 3 months in both trials
LDL concentration will be measured in blood
Changes in triglycerides
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Triglycerides concentration will be measured in blood
Changes in free fatty acids
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Free fatty acid concentration will be measured in blood
Changes in glutathione
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Oxidized (GSH) and reduced (GSSG) glutathione will be measured in red blood cell lysate
Changes in bone status
时间窗: At baseline as well as at 1,5 and 3 months in both trials
Bone mineral density and bone mineral content will be assessed in hole body, spine and hips using DXA
次要结局
- Changes in body weight(At baseline as well as at 1,5 and 3 months in both trials)
- Changes in muscle architecture(At baseline as well as at 1,5 and 3 months in both trials)
研究者
Athanasios Chatzinikolaou
Associate Professor
Democritus University of Thrace
